HK1206026A1 - 種 激酶抑制劑的硫酸氫鹽及其製備方法 - Google Patents
種 激酶抑制劑的硫酸氫鹽及其製備方法Info
- Publication number
- HK1206026A1 HK1206026A1 HK15106673.4A HK15106673A HK1206026A1 HK 1206026 A1 HK1206026 A1 HK 1206026A1 HK 15106673 A HK15106673 A HK 15106673A HK 1206026 A1 HK1206026 A1 HK 1206026A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- jak
- bisulfate
- kinase inhibitor
- preparation methods
- jak kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310227683 | 2013-06-07 | ||
| PCT/CN2014/076794 WO2014194741A1 (zh) | 2013-06-07 | 2014-05-05 | 一种jak激酶抑制剂的硫酸氢盐及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1206026A1 true HK1206026A1 (zh) | 2015-12-31 |
Family
ID=52007520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106673.4A HK1206026A1 (zh) | 2013-06-07 | 2015-07-13 | 種 激酶抑制劑的硫酸氫鹽及其製備方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9422300B2 (zh) |
| EP (1) | EP3006445B1 (zh) |
| JP (1) | JP6323885B2 (zh) |
| KR (1) | KR102275326B1 (zh) |
| CN (1) | CN104470927B (zh) |
| AU (1) | AU2014277506B2 (zh) |
| BR (1) | BR112015029463B1 (zh) |
| CA (1) | CA2913194C (zh) |
| ES (1) | ES2655074T3 (zh) |
| HK (1) | HK1206026A1 (zh) |
| HU (1) | HUE036533T2 (zh) |
| MX (1) | MX2015016513A (zh) |
| PT (1) | PT3006445T (zh) |
| RU (1) | RU2665680C2 (zh) |
| TW (1) | TWI641609B (zh) |
| WO (1) | WO2014194741A1 (zh) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105566327A (zh) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
| EP3216790B1 (en) | 2014-11-05 | 2019-10-02 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof |
| CA3014090A1 (en) * | 2016-02-19 | 2017-08-24 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof |
| JP6937828B2 (ja) * | 2016-11-23 | 2021-09-22 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ピロロ６員複素芳香環誘導体の製造方法、および中間体 |
| TW201827436A (zh) * | 2017-01-20 | 2018-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法 |
| JP2021503505A (ja) * | 2017-11-20 | 2021-02-12 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | 局所投与用の医薬組成物およびその調製方法 |
| MX2021005334A (es) * | 2018-11-05 | 2021-06-23 | Avista Pharma Solutions Inc | Compuestos quimicos. |
| CN111205290B (zh) * | 2018-11-22 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的结晶形式及其制备方法 |
| CN111440127B (zh) * | 2019-01-17 | 2022-07-26 | 青岛农业大学 | 一种噻唑酰胺类化合物及其制备和应用 |
| JP2022546760A (ja) * | 2019-09-05 | 2022-11-08 | ウニベルズィテート ベルン | 三環式ヤヌスキナーゼ（ｊａｋ）阻害剤および自己免疫疾患の治療におけるそれらの使用 |
| CN113698404B (zh) * | 2020-05-21 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种低溶剂残留的六氢环戊并[c]吡咯-2(1H)-甲酰胺化合物及其制备方法 |
| AU2021318201A1 (en) | 2020-07-28 | 2023-02-02 | Arcutis Biotherapeutics, Inc. | Topical formulation containing jak inhibitor and laureth-4 |
| JP2023550363A (ja) | 2020-11-17 | 2023-12-01 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | 深部皮膚薬物送達のための組成物および方法 |
| CN112457272B (zh) * | 2020-12-02 | 2022-04-19 | 上海再启生物技术有限公司 | (3-甲氧基-1,2,4-噻二唑-5-氨基)甲酸苯酯的制备方法 |
| WO2023114832A1 (en) | 2021-12-15 | 2023-06-22 | Arcutis Biotherapeutics, Inc. | Stable formulations of shr0302 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423120T1 (de) * | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
| PT1613315E (pt) * | 2003-04-04 | 2009-04-22 | Novartis Ag | Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias |
| GB0307856D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
| CN101142218B (zh) * | 2005-02-03 | 2013-02-06 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡咯并嘧啶 |
| CN102822177A (zh) * | 2010-02-05 | 2012-12-12 | 美国辉瑞有限公司 | 吡咯并[2,3-d]嘧啶脲化合物 |
| EP2721025B1 (en) * | 2011-06-16 | 2015-11-25 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| AU2012357296B2 (en) * | 2011-12-21 | 2017-04-13 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof |
-
2014
- 2014-05-05 KR KR1020157035615A patent/KR102275326B1/ko active IP Right Grant
- 2014-05-05 US US14/895,117 patent/US9422300B2/en active Active
- 2014-05-05 HU HUE14807030A patent/HUE036533T2/hu unknown
- 2014-05-05 EP EP14807030.3A patent/EP3006445B1/en active Active
- 2014-05-05 CA CA2913194A patent/CA2913194C/en active Active
- 2014-05-05 PT PT148070303T patent/PT3006445T/pt unknown
- 2014-05-05 CN CN201480001854.XA patent/CN104470927B/zh active Active
- 2014-05-05 WO PCT/CN2014/076794 patent/WO2014194741A1/zh active Application Filing
- 2014-05-05 RU RU2015156142A patent/RU2665680C2/ru active
- 2014-05-05 BR BR112015029463-4A patent/BR112015029463B1/pt active IP Right Grant
- 2014-05-05 MX MX2015016513A patent/MX2015016513A/es active IP Right Grant
- 2014-05-05 AU AU2014277506A patent/AU2014277506B2/en active Active
- 2014-05-05 ES ES14807030.3T patent/ES2655074T3/es active Active
- 2014-05-05 JP JP2016517135A patent/JP6323885B2/ja active Active
- 2014-05-14 TW TW103116955A patent/TWI641609B/zh active
-
2015
- 2015-07-13 HK HK15106673.4A patent/HK1206026A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI641609B (zh) | 2018-11-21 |
| MX2015016513A (es) | 2016-04-15 |
| BR112015029463A2 (pt) | 2017-07-25 |
| KR102275326B1 (ko) | 2021-07-12 |
| KR20160032021A (ko) | 2016-03-23 |
| BR112015029463B1 (pt) | 2023-01-10 |
| WO2014194741A1 (zh) | 2014-12-11 |
| JP6323885B2 (ja) | 2018-05-16 |
| RU2015156142A3 (zh) | 2018-03-19 |
| CA2913194C (en) | 2021-03-02 |
| HUE036533T2 (hu) | 2018-07-30 |
| RU2665680C2 (ru) | 2018-09-04 |
| EP3006445B1 (en) | 2017-11-15 |
| ES2655074T3 (es) | 2018-02-16 |
| CN104470927A (zh) | 2015-03-25 |
| RU2015156142A (ru) | 2017-07-17 |
| CN104470927B (zh) | 2016-05-04 |
| TW201514180A (zh) | 2015-04-16 |
| JP2016520134A (ja) | 2016-07-11 |
| US9422300B2 (en) | 2016-08-23 |
| EP3006445A1 (en) | 2016-04-13 |
| AU2014277506A1 (en) | 2016-01-21 |
| CA2913194A1 (en) | 2014-12-11 |
| US20160102098A1 (en) | 2016-04-14 |
| EP3006445A4 (en) | 2016-11-23 |
| AU2014277506B2 (en) | 2017-08-31 |
| PT3006445T (pt) | 2018-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1206026A1 (zh) | 種 激酶抑制劑的硫酸氫鹽及其製備方法 | |
| HK1223089A1 (zh) | 激酶抑制劑及其用途 | |
| HK1219421A1 (zh) | 激酶抑制劑的組合及其用途 | |
| GB2517079B (en) | Security devices and methods of manufacture | |
| HRP20170840T4 (hr) | Supstituirani ksantini i metode njihove uporabe | |
| GB2535360B (en) | Methods of preparing polyhemiaminals and polyhexahydrotriazines | |
| SG11201600707QA (en) | Substituted aminopyrimidine compounds and methods of use | |
| GB201301790D0 (en) | Security devices and methods of manufacture thereof | |
| GB2510381B (en) | Security devices and methods of manufacture thereof | |
| GB201401761D0 (en) | Security devices and methods of manufacture thereof | |
| IL244268A0 (en) | Heterocyclic compounds and methods of use | |
| HK1224307A1 (zh) | 原毒素- 變體及其使用方法 | |
| SG11201507389RA (en) | Integration of hydro-dechlorination and hydro-regeneration | |
| IL241290A0 (en) | Subprevir polymorphs and methods for their production | |
| IL225693A0 (en) | Three-phase choke and the manufacturing method | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors | |
| AU5220P (en) | Jewel of DesertTopaz Delosperma cooperi |